Reduction of skin-homing cytotoxic T cells (CD8+-CLA+) in patients with vitiligo

Photodermatology Photoimmunology and Photomedicine

Volumn 27, Issue 1, 2011, Pages 40-44

  Antelo, Daniela Pereira ^a   Filgueira, Absalom Lima ^a   Cunha, José Marcos Telles ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cutaneous lymphocyte associated antigen; Photochemotherapy; T lymphocytes; Vitiligo

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTE TYPING; MALE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; SKIN DEFECT; VITILIGO;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PUVA THERAPY; STATISTICS, NONPARAMETRIC; VITILIGO; YOUNG ADULT;

EID: 78650786333     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2010.00563.x     Document Type: Article

References (34)

1. Bos JD. Skin immune system (SIS), 2nd edn. Boca Raton/New York: CRC Press, 1997.
2. Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol 1997; 15: 845-851.
3. Kemp EHW, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65-77.
4. Antelo DP, Filgueira AL, Cunha JMT. Aspectos imunopatológicos do vitiligo. Med Cutan Ibero Lat Am 2008; 36: 125-136.
5. Horn TD, Abanmi A. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Dermatopathol 1997; 19: 400-402.
6. Le Poole IC, van den Wijngaard R, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148: 1219-1228.
7. Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol 1983; 22: 477-480.
8. Hann SK, Park YK, Chung KY, Kim HY, Won JH. Peripheral blood lymphocyte imbalance in Koreans with active vitiligo. Int J Dermatol 1993; 32: 286-289.
9. Montes LF, Abulafia J, Wilborn WH, Hyde BM, Montes CM. Value of histopathology in vitiligo. Int J Dermatol 2003; 42: 57-61.
10. Aslanian FMNP, Noé RAM, Cuzzi T, Filgueira AL. Abnormal histological findings in active vitiligo include the normal-appearing skin. Pigment Cell Res 2007; 20: 144-145.
11. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+T cells at the perilesional site. Lab Invest 2000; 80: 1299-1309.
12. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188: 1203-1208.
13. Palermo B, Campanelli R, Garbelli S, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001; 117: 326-332.
14. Le Gal FA, Avril MF, Bosq J, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 2001; 117: 1464-1470.
15. Ortonne JP, Alario A. T and B lymphocytes in vitiligo. Arch Dermatol Res 1978; 261: 147-151.
16. Soubiran P, Benzaken S, Bellet C, Lacour JP, Ortonne JP. Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br J Dermatol 1985; 113 (Suppl 28): 124-127.
17. Grimes PE, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L. T cell profiles in vitiligo. J Am Acad Dermatol 1986; 14 (Part 1): 196-201.
18. Halder RM, Walters CS, Johnson BA, Chakrabarti SG, Kenney JA Jr. Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol 1986; 14 (Part 1): 733-737.
19. D'Amelio R, Frati C, Fattorossi A, Aiuti F. Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives. Ann Allergy 1990; 65: 143-145.
20. Mozzanica N, Frigerio U, Finzi AF, et al. T cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990; 22 (Part 1): 223-230.
21. Abdel-Naser MB, Ludwig WD, Gollnick H, Orfanos CE. Nonsegmental vitiligo: decrease of the CD45RA+T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 1992; 31: 321-326.
22. Mahmoud F, Abul H, al-Saleh Q, Haines D, Burleson J, Morgan G. Peripheral T-cell activation in non-segmental vitiligo. J Dermatol 1998; 25: 637-640.
23. Gunduz K, Ozturk G, Terzioglu E, Sebik F. T cell subpopulations and IL-2R in vitiligo. J Dermatol 2004; 31: 94-97.
24. Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Berg J, Auböck J. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+/CD8+T-cell ratio. Wien Med Wochenschr 2009; 159: 337-341.
25. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341: 1817-1828.
26. Santamaria-Babi LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol 2004; 14: 13-18.
27. Sigmundsdottir H, Gudjonsson JE, Valdimarsson H. The effects of ultraviolet B treatment on the expression of adhesion molecules by circulating T lymphocytes in psoriasis. Br J Dermatol 2003; 148: 996-1000.
28. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997; 15: 921-926.
29. Zanolli MD, Feldman S, Clark AR, Fleischer AB. Phototherapy treatment protocols. New York: The Parthenon Publishing Group, 2000.
30. Lang KS, Caroli CC, Muhm A, et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001; 116: 891-897.
31. Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, et al. Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2008; 121: 148-157, e3.
32. Aslanian FMNP, Noé RAM, Antelo DP, et al. Immunohistochemical findings in active vitiligo including depigmenting lesions and non-lesional skin. Open Derm J 2008; 2: 113-118.
33. Antelo DP, Filgueira AL, Cunha JMT. Redução dos linfócitos TCD8+ citotóxicos observada com a terapia Puva em paciente com vitiligo. An Bras Dermatol 2008; 83: 572-574.
34. Tsuchiyama J, Yoshino T, Saito T, et al. Cutaneous lymphocyte antigen-positive T cells may predict the development of acute GVHD: alterations and differences of CLA+T- and NK-cell fractions. Bone Marrow Transplant 2009; 43: 863-873.